Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases (Q72326112)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

title

Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

1 reference

U Keilholz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

C Scheibenbogen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M Brado

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

P Georgi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

D Maclachlan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

B Brado

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

W Hunstein

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

25 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

volume

30A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

page(s)

103-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

25 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Regional administration of lymphokine-activated killer cells can be superior to intravenous application

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Relapse in the central nervous system in melanoma patients successfully treated with biomodulators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

Interleukin-2 therapy for metastatic uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980028-0

7 January 2021

10.1016/S0959-8049(05)80028-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8142149%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

1 reference